Bio Blast Pharma Ltd. (ORPN)
(Delayed Data from NSDQ)
$11.50 USD
0.00 (0.00%)
Updated Mar 25, 2019 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Enlivex Therapeutics Ltd. [ORPN]
Reports for Purchase
Showing records 1 - 20 ( 68 total )
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
ValuEngine Detailed Valuation Report for ORPN
Provider: ValuEngine, Inc
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
We are terminating our coverage due to reallocation of resources within the research department
Provider: H.C. Wainwright & Co., Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
We are hereby terminating our coverage due to reallocation of resources within the research department.
Provider: Rodman & Renshaw, Co.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
We are dropping coverage of ORPN shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
We are transferring coverage of ORPN to Sa''ar Yaniv, due to the departure of the covering analyst and placing shares Under Review
Provider: Roth Capital Partners, Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Lowering Price Target to $9 From $19 Based on Higher Discount Rate for Trehalose; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Lowering Price Target to $9 From $19 Based on Higher Discount Rate for Trehalose; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
3Q16 Results; Gearing Up for OPMD Phase IIb
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
MTD Study Points to 2x Dosing Above HOPEMD; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Extension Study Data Continue to Point in Right Direction for OPMD
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
2Q16 Results; Looking to Build on HOPEMD Efficacy Next Year
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Reducing Price Target to $19 Per Share Based on Outlook; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Enlivex Therapeutics Ltd.
Industry: Medical - Drugs
Reducing Price Target to $19 Per Share Based on Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.